Funding for this research was provided by:
Universiteit van Amsterdam (Innovation Grant)
Received: 30 March 2020
Accepted: 16 June 2020
First Online: 17 July 2020
Ethics approval and consent to participate
: The study protocol was approved by the ethics review board of the Academic Medical Center (AMC) at the University of Amsterdam (Amsterdam, The Netherlands). The OPTIMACT trial was registered in The Netherlands National Trial Register under number NTR6163. Written informed consent was obtained from all subjects (patients) in this study.
: Not applicable.
: The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.